Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
Interstitial lung disease
•
CTD-ILD
•
Pulmonary
Would you add abatacept to treat active inflammatory arthritis in a patient with history of RA-ILD who is already taking mycophenolate?
Related Questions
Do you avoid the use of TNF inhibitors in patients with RA-ILD?
Would nintedanib offer benefit to a patient with scleroderma (Anti-Th/To+/SSA+) who has CT chest with typical UIP pattern?
In light of the RECITAL study, would rituximab be a reasonable choice in a patient with PL-12 antibodies, rapidly progressive pulmonary disease with organizing pneumonia on biopsy?
How would you approach rheumatoid arthritis treatment for widespread large rheumatoid nodules but no active synovitis or subjective joint pain?
Can you use leflunomide and rituximab in a patient with both multiple sclerosis and rheumatoid arthritis?
What indicators do you use to determine whether a patient is having a favorable or unfavorable response to nintedanib?
What would be your approach to a patient with new diagnosis of seropositive rheumatoid arthritis manifesting as a constrictive pericarditis with no joint pain complaints?
Would you prescribe a JAK inhibitor in patients with baseline transaminase elevation?
Do you consider immunosuppressive agents in progressive interstitial pneumonias or pneumonitis without a clear driving etiology?
Are there concerns with combining anti-IL5 biologics (mepolizumab or benralizumab) for severe asthma with other biologics for RA (e.g. TNFi)?
